Document is current
Any future updates will be listed below
-
Authors
Tebani, Abdellah
Guenet, David
Torre, Stéphanie
Arion, Alina
Héron, Bénédicte
Brassier, Anais
Belmatoug, Nadia
Ausseil, Jérôme
Bruel, Henri
Lévéque, Catherine
Goldenberg, Alice
Gruchy, Nicolas
Apetrei, Andreea
Bach, Nathalie
Guerrot, Anne-Marie
Samaan, Simon
Ducatez, Franklin
Marret, Stéphane
Bekri, Soumeya https://orcid.org/0000-0001-6184-7270
-
Funding
Funding for this research was provided by:
Takeda Pharmaceutical Company
Alexion Pharmaceuticals
Ultragenyx Pharmaceutical
BioMarin Pharmaceutical
Revvity Cerba
- License Information
-
More Information
Article History
Received: 16 September 2025
Accepted: 26 May 2026
First Online: 29 May 2026
Competing interests
: S.B. and A.T. reported receiving grants from Sanofi, Takeda, Orchard Therapeutics, Ultragenyx, Alexion, Biomarin, Cerba, and Revvity to conduct this study. No other disclosures were reported.
